Laboratory Identification of Lupus Anticoagulants

Abstract

The main laboratory characteristic of lupus anticoagulants (LA) is their ability to prolong phospholipid-dependent clotting time in vitro. The laboratory demonstration of LA requires a systematic approach combined with an awareness of the many variables that can affect test results. The ideal testing procedures are those sensitive enough to detect weak LA and specific enough so as not to produce incorrect conclusions. International guidelines have been published to assist laboratories in applying correct testing processes. The most recently published guidelines from the International Society on Thrombosis and Haemostasis update the criteria for detecting the presence of LA that were presented in the 1995 guidelines. Some of the specific recommendations relate to the key areas of setting cut-off levels for screening, mixing, and confirmatory procedures. The more challenging aspects of testing for LA include maintaining sensitivity and specificity of the assays, especially in the presence of anticoagulant therapy.

Keywords

lupus anticoagulant - diluted Russell viper venom time - activated partial thromboplastin time - mixing test

• References

• 1 Pengo V, Tripodi A, Reber G , et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
• 2 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74 (4) 1185-1190
• 3 Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost 1991; 65 (3) 320-322
• 4 Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109 (4) 704-715
• 5 Moffat KA, Ledford-Kraemer MR, Plumhoff EA , et al. Are laboratories following published recommendations for lupus anticoagulant testing? An international evaluation of practices. Thromb Haemost 2009; 101 (1) 178-184
• 6 Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology 2011; 43 (7) 682-692
• 7 Brandt JT, Triplett DA, Rock WA, Bovill EG, Arkin CF. Effect of lupus anticoagulants on the activated partial thromboplastin time. Results of the College of American Pathologists survey program. Arch Pathol Lab Med 1991; 115 (2) 109-114
• 8 Tripodi A, Biasiolo A, Chantarangkul V, Pengo V. Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin Chem 2003; 49 (10) 1608-1614
• 9 Detarsio GA, Soler C, Paredes J, Milani AC, Ordi-Ros J. Lupus anticoagulant: sensitivity of 19 commercial activated partial thromboplastin time reagents. Acta Bioquim Quin Latinoam 2007; 41: 733-739
• 10 Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulant: results of the second international workshop for identification of lupus anticoagulant. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995; 74 (6) 1597-1603
• 11 Rosner E, Pauzner R, Lusky A, Modan M, Many A.. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost 1987; 57 (2) 144-147
• 12 Chang SH, Tillema V, Scherr DA. A “percent correction” formula for evaluation of mixing studies. Am J Clin Pathol 2002; 117 (1) 62-73
• 13 Moore GW, Savidge GF. The dilution effect of equal volume mixing studies compromises confirmation of inhibition by lupus anticoagulants even when mixture specific reference ranges are applied. Thromb Res 2006; 118 (4) 523-528
• 14 Solberg HE. The theory of reference values Part 5. Statistical treatment of collected reference values. Determination of reference limits. J Clin Chem Clin Biochem 1983; 21 (11) 749-760
• 15 Tripodi A. More on: criteria to define the antiphospholipid syndrome. J Thromb Haemost 2008; 6 (6) 1049-1050
• 16 Aboud MR, Roddie C, Ward CM, Coyle L. The laboratory diagnosis of lupus anticoagulant in patients on oral anticoagulation. Clin Lab Haematol 2006; 28 (2) 105-110
• 17 Favaloro EJ, Reben R, Mohammed S, Koutts J. A clinical audit of antiphospholipid antibody testing in tertiary practice. Towards improved relevance in thrombophilia investigations?. Intern Med J 2012; 42 (4) 427-434
• 18 Favaloro EJ, Mohammed S, Pati N, Ho MY, McDonald D. A clinical audit of congenital thrombophilia investigation in tertiary practice. Pathology 2011; 43 (3) 266-272
• 19 Jacobsen EM, Trettenes EJ, Wisløff F, Abildgaard U. Detection and quantification of lupus anticoagulants in plasma from heparin treated patients, using addition of polybrene. Thromb J 2006; 4: 3
• 20 Gosselin RC, King JH, Janatpur KA, Dager WH, Larkin EC, Owings JT. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing. Arch Pathol Lab Med 2004; 128 (10) 1142-1145
• 21 van Ryn J, Stangier J, Haertter S , et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103 (6) 1116-1127
• 22 Hillarp A, Baghaei F, Fagerberg Blixter I , et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9 (1) 133-139
• 23 van Os GMA, de Laat B, Kamphuisen PW, Meijers JCM, de Groot PG. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost 2011; 9 (8) 1657-1659
• 24 Devreese KMJ. No more mixing tests required for integrated assay systems in the laboratory diagnosis of lupus anticoagulants?. J Thromb Haemost 2010; 8 (5) 1120-1122
• 25 Aboud MR, Roddie C, Ward C, Coyle L. To mix with pooled normal plasma or not to mix: a comparative study of two approaches for assessing lupus anticoagulant inhibitory activity in the dilute Russell viper venom method. Clin Chem 2007; 53: 143-145
• 26 Thom J, Ivey L, Eikelboom J. Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant. J Thromb Haemost 2003; 1 (12) 2689-2691
• 27 Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA, Wisløff F. The Lupus Ratio test-an interlaboratory study on the detection of lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test. Fifth international survey of lupus anticoagulants–ISLA 5. Thromb Haemost 2000; 83 (5) 704-708
• 28 Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993; 70 (5) 787-793
• 29 Favaloro EJ, Bonar R, Zebeljan D, Kershaw G, Marsden K. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2010; 8 (12) 2828-2831
• 30 Bonar R, Favaloro EJ, Zebeljan D , et al. Evaluating laboratory approaches to the identification of lupus anticoagulants: a diagnostic challenge from the RCPA Haematology QAP. Pathology 2012; 44 (3) 240-247
• 31 Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: part II—lupus anticoagulant. Semin Thromb Hemost 2012; 38 (4) 404-411